VEGF-B antibody and interleukin-22 fusion protein ameliorates diabetic nephropathy through inhibiting lipid accumulation and inflammatory responses

VEGF-B antibody and interleukin-22 fusion protein ameliorates diabetic nephropathy through inhibiting lipid accumulation and inflammatory responses

Diabetic nephropathy (DN) is considered the primary causes of end-stage renal disease (ESRD) and is related to abnormal glycolipid metabolism, hemodynamic abnormalities, oxidative stress and chronic inflammation. Antagonism of vascular endothelial growth factor B (VEGF-B) could efficiently ameliorat...

Full description

Bibliographic Details
Main Authors: Yilan Shen, Wei Chen, Lei Han, Qi Bian, Jiajun Fan, Zhonglian Cao, Xin Jin, Tao Ding, Zongshu Xian, Zhiyong Guo, Wei Zhang, Dianwen Ju, Xiaobin Mei
Format: Article
Language:English
Published: Elsevier 2021-01-01
Series:Acta Pharmaceutica Sinica B
Subjects:
Diabetic nephropathy
Vascular endothelial growth factor B
Interleukin-22
Fusion protein
Online Access:http://www.sciencedirect.com/science/article/pii/S2211383520306286

Similar Items

Similar Items